Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Repare Therapeutics ( (RPTX) ).
Repare Therapeutics has signed an asset purchase agreement for Gilead Sciences to acquire its Polθ ATPase inhibitor RP-3467 for up to $30 million in total consideration, including a $25 million upfront payment and an additional $5 million tied to completion of technology transfer. The deal marks Repare’s third and most significant portfolio transaction this year and directly boosts the company’s cash balance, in turn increasing the estimated per-share cash payout that Repare shareholders are expected to receive under its separate planned acquisition by XenoTherapeutics to approximately $2.20 per common share at closing, pending shareholder approval of the arrangement.
The most recent analyst rating on (RPTX) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Repare Therapeutics stock, see the RPTX Stock Forecast page.
Spark’s Take on RPTX Stock
According to Spark, TipRanks’ AI Analyst, RPTX is a Neutral.
Repare Therapeutics’ overall stock score is driven by positive technical indicators and promising corporate developments, despite financial challenges and poor valuation metrics. The company’s strong cash position and recent trial data provide a foundation for potential future improvements.
To see Spark’s full report on RPTX stock, click here.
More about Repare Therapeutics
Repare Therapeutics is a clinical-stage precision oncology company that uses a proprietary synthetic lethality approach to discover and develop highly targeted cancer therapies focused on genomic instability and DNA damage repair. Its pipeline includes novel therapeutics such as RP-3467, a small-molecule inhibitor of polymerase theta (Polθ) being tested in a Phase 1 POLAR trial in patients with various advanced solid tumors, including ovarian, breast, prostate and pancreatic cancers.
Average Trading Volume: 835,233
Technical Sentiment Signal: Hold
Current Market Cap: $109.9M
See more insights into RPTX stock on TipRanks’ Stock Analysis page.